Literature DB >> 940593

Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine.

E Müller-Schweinitzer.   

Abstract

Changes in tension of spiral strips from dog saphenous, external carotid and basilar arteries were monitored isometrically. Serotonin (5-HT) contracted the 3 arterial preparations in about the same concentration range. Compared with noradrenaline (NA) (100%) the efficacy of 5-HT was about 60% on saphenous, 150% on external carotid and about 500% on basilar arteries. Ergotamine (E) stimulated the 3 vascular preparations in concentrations about 100 times lower than 5-HT. Compared with NA the efficacy of E was about 20% on saphenous, 50% on external carotid and 200% on basilar arteries. Compared with 5-HT (100%) however, E had similar constrictor activities in the 3 arteries. It seemed likely therefore that 5-HT receptors are involved in the vasoconstrictor activity of E. Evidence for this was obtained in experiments in which cyproheptadine (Cy), a 5-HT antagonist, was used. For antagonism of E concentrations of Cy about 6 times higher than those required to inhibit 5-HT were necessary, whereas for antagonism of NA about 500 times higher Cy concentrations were necessary. The results suggest that on canine arterial vascular smooth muscle the constrictor activity of E is mediated mainly through serotoninergic receptor sites.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 940593     DOI: 10.1007/bf00498580

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  EFFECT OF VARIOUS PHARMACOLOGIC AGENTS ON CEREBRAL ARTERIES.

Authors:  P KARLSBERG; H W ELLIOTT; J E ADAMS
Journal:  Neurology       Date:  1963-09       Impact factor: 9.910

2.  Method for isometric recording from isolated vessels under various conditions.

Authors:  P RONDELL; F GROSS
Journal:  Helv Physiol Pharmacol Acta       Date:  1960

3.  The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog.

Authors:  A CARPI; M VIRNO
Journal:  Br J Pharmacol Chemother       Date:  1957-06

Review 4.  Current concepts in the pathogenesis and interval treatment of migraine.

Authors:  M Anthony; J W Lance
Journal:  Drugs       Date:  1972       Impact factor: 9.546

5.  Effects of dopamine, noradrenaline and 5-hydroxytryptamine on the cerebral blood flow in the dog.

Authors:  C von Essen
Journal:  J Pharm Pharmacol       Date:  1972-08       Impact factor: 3.765

6.  Proceedings: Receptors for 5-hydroxytryptamine and noradrenaline in rabbit aorta and central ear artery.

Authors:  E Apperley; P P Humphrey; G P Levy
Journal:  Br J Pharmacol       Date:  1974-09       Impact factor: 8.739

7.  Studies on the mechanism of the venoconstrictor activity of ergotamine on isolated canine saphenous veins.

Authors:  E Müller-Schweinitzer; E Stürmer
Journal:  Blood Vessels       Date:  1974

8.  Proceedings: Further studies on the mode of action of ergotamine on canine vein strips.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

9.  Pharmacological comparison of prostaglandin F 2a' serotonin and norepinephrine on cerebrovascular tone of monkey.

Authors:  R P White; J A Heaton; I C Denton
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

10.  Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects.

Authors:  D A Curran; H Hinterberger; J W Lance
Journal:  Brain       Date:  1965-12       Impact factor: 13.501

View more
  12 in total

Review 1.  A basis for migraine therapy- the autonomic theory reappraised.

Authors:  E S Johnson
Journal:  Postgrad Med J       Date:  1978-04       Impact factor: 2.401

2.  Inhibition by Cd2+ verapamil and papaverine of Ca2+-induced contractions in isolated cerebral and peripheral arteries of the dog.

Authors:  S Hayashi; N Toda
Journal:  Br J Pharmacol       Date:  1977-05       Impact factor: 8.739

3.  Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; N T Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

4.  Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine.

Authors:  V Ala-Hurula
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Regional differences in the responsiveness of isolated arteries from cattle, dog and man.

Authors:  E Müller-Schweinitzer; H Weidmann
Journal:  Agents Actions       Date:  1977-09

6.  Actions of co-dergocrine mesylate and its components at vascular smooth muscle.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-02       Impact factor: 3.000

7.  Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism.

Authors:  P D Henry; M Yokoyama
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

8.  Comparative studies on the effects of tolmesoxide (Rx71107), a tolmesoxide metabolite (Rx71112) and nifedipine in isolated blood vessels.

Authors:  E Mikkelsen; O L Pedersen
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

9.  Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; J Heikkilä; N Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

10.  Effects of 5-hydroxytryptophol, a 5-hydroxytryptamine metabolite, on isolated cerebral arteries of the dog.

Authors:  L H Wang Fu; S Hayashi; N Toda
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.